Single Biggest Cancer Dictionary in the World
What is anti-PRAME T-cell receptor/anti-CD3 scFv fusion protein IMC-F106C?
Pronunciation: /ˈænˌti prame* ti sɛl riˈsɛptər ˈænˌti ˈsiˈdi θri scfv* fˈjuʒən ˈproʊˌtin imc* ɛf wən ˈhənərd ənd sɪks si/
anti-PRAME T-cell receptor/anti-CD3 scFv fusion protein IMC-F106C
Definition
A T-cell re-directing bi-specific biologic composed of a modified form of human T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) and fused to an anti-CD3 single-chain variable fragment (scFv), with potential antineoplastic activity. Upon administration of IMC-F106C, the TCR moiety of this agent targets and binds to PRAME on tumor cells and the anti-CD3 scFv moiety binds to CD3- expressing T lymphocytes. This selectively cross-links tumor cells and T lymphocytes and results in a CTL-mediated death of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.